ArticleBreast cancer research : BCR2026
TFRC promotes ferroptosis to suppress breast cancer bone metastasis via the activation of HIF-1 pathway.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer with bone metastasis remains a significant clinical challenge. Ferroptosis, an iron-dependent cell death process, may influence metastasis. However, the role of key regulators like transferrin receptor (TFRC) is unclear.
methodsTranscriptome sequencing identified ferroptosis-related differentially expressed genes (DEGs) in tibial tumors from a breast cancer mouse model with bone metastasis versus breast cancer cells. Hub genes were identified via protein-protein interaction network analysis. The function of TFRC was validated in vitro (MCF-7 and MDA-MB-231) through gain/loss-of-function studies combined with ferroptosis modulators (Erastin, Ferrostatin-1) and in a BALB/c nude mouse intratibial model. Cell apoptosis, proliferation, invasion, and migration were evaluated by flow cytometry, cell-counting kit-8, Transwell, and wound healing assays, respectively. Ferroptosis markers and epithelial-mesenchymal transition-related proteins were assessed. The involvement of the hypoxia-inducible factor-1 (HIF-1) pathway was investigated using the HIF-1α inhibitor PX-478.
resultsBioinformatics identified 22 ferroptosis-related DEGs, with TFRC among the top 10 hub genes significantly downregulated in bone metastasis, a finding corroborated in human clinical specimens. Overexpressing TFRC in vivo suppressed tumor growth, upregulated E-cadherin, downregulated N-cadherin, and promoted ferroptosis. In vitro, TFRC overexpression consistently inhibited malignant phenotypes and induced ferroptosis in both cell lines, effects reversible by ferroptosis inhibition. Conversely, ferroptosis activation upregulated TFRC expression, and TFRC knockdown attenuated cellular sensitivity to ferroptosis inducers, indicating a reciprocal regulatory relationship. Mechanistically, HIF-1 pathway was identified as the downstream pathway of TFRC, and TFRC overexpression upregulated HIF-1α. PX-478 attenuated TFRC-mediated ferroptosis induction and suppression of malignancy.
conclusionTFRC inhibits bone metastasis in breast cancer by promoting ferroptosis via HIF-1α activation, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.